ArticleThe ISME journal2021
Mucin-derived O-glycans supplemented to diet mitigate diverse microbiota perturbations.
Article in The ISME journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 105 citations in OpenAlex.
- Mucin-degrading gut bacteria: context-dependent roles in intestinal homeostasis and disease.Gut microbes · 2026Review
- Deciphering themSphere · 2026Article
- Soy and the gut microbiome: a bi-directional relationship shaping nutrition and health.European journal of nutrition · 2026Review
- Berberine Ameliorates DSS-Induced Colitis via Regulation of Mucosal Barrier Homeostasis and Mucin-Degrading Microbiota.International journal of molecular sciences · 2026Article
- Efficient mucin O-glycan degradation by specific mucin degrading intestinal bacteria: towards understanding enzyme-glycan interactions.Glycobiology · 2026Article
- MUC2 shifts the metabolic profiles of commensal bacteria in defined microbial communities.Microbiome research reports · 2026Article
- Breaking down barriers: is intestinal mucus degradation byInfection and immunity · 2025Review
- Milk and mucin glycans orchestrate a synthetic infant gut microbiota structure.FEMS microbiology ecology · 2025Article
- The role of glycosylated mucins in maintaining intestinal homeostasis and gut health.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Review
- The effect of dietary transition on infant microbiota composition and metabolic activity captured with the simulator of the human intestinal microbial ecosystem (SHIME).Gut microbiome (Cambridge, England) · 2025Article
- The gastric microbiome altered by A4GNT deficiency in mice.Frontiers in microbiology · 2025Article
- Review
- Dietary fibers boost gut microbiota-produced B vitamin pool and alter host immune landscape.Microbiome · 2024Article
- ComprehensiveAnalytical chemistry · 2024Article
- Mucin alleviates colonic barrier dysfunction by promoting spermine accumulation through enhanced arginine metabolism inmSystems · 2024Article
- Antibiotic perturbations to the gut microbiome.Nature reviews. Microbiology · 2023Review
- Metagenomic Immunoglobulin Sequencing (MIG-Seq) Exposes Patterns of IgA Antibody Binding in the Healthy Human Gut Microbiome.bioRxiv : the preprint server for biology · 2023Article
- Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Origins and Evolution of NovelbioRxiv : the preprint server for biology · 2023Article
- Microbiota-accessible carbohydrates (MACs) as novel gut microbiome modulators in noncommunicable diseases.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Microbiota-accessible carbohydrates (MACs) are powerful modulators of microbiota composition and function. These substrates are often derived from diet, such as complex polysaccharides from plants or human milk oligosaccharides (HMOs) during breastfeeding. Host-derived mucus glycans on gut-secreted mucin proteins serve as a continuous endogenous source of MACs for resident microbes; here we investigate the potential role of purified, orally administered mucus glycans in maintaining a healthy microbial community. In this study, we liberated and purified O-linked glycans from porcine gastric mucin and assessed their efficacy in shaping the recovery of a perturbed microbiota in a mouse model. We found that porcine mucin glycans (PMGs) and HMOs enrich for taxonomically similar resident microbes. We demonstrate that PMGs aid recovery of the microbiota after antibiotic treatment, suppress Clostridium difficile abundance, delay the onset of diet-induced obesity, and increase the relative abundance of resident Akkermansia muciniphila. In silico analysis revealed that genes associated with mucus utilization are abundant and diverse in prevalent gut commensals and rare in enteric pathogens, consistent with these glycan-degrading capabilities being selected for during host development and throughout the evolution of the host-microbe relationship. Importantly, we identify mucus glycans as a novel class of prebiotic compounds that can be used to mitigate perturbations to the microbiota and provide benefits to host physiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.